• About Us
  • Strategy
  • Our Team
  • Portfolio
  • News
  • Contact
  • Building Market-Leading Healthtech Companies

    About Us
    Header Pattern

    Sector Focus

    Medical Devices

    Tools & Diagnostics

    Digital Health

    Tech-Enabled Services

    Our Strategy


    Leaders in Healthcare Technology Investing

    See All
    Ai Cure StandardLogo retinaCogentix Logo RGB 300x96EndoKeystone 1Med Minder removebg previewNeuro Pace Logo Vert rgb largeStrataVeranexMinerva logo reg 2xSknv


    "We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”

    Meet Our Team
    active portfolio companies
    employees worldwide
    AP-II Investments to Date
    successful exits


    Apr 01, 2024

    Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

    In a landmark clinical study, this innovative adjunctive treatment delivered via smartphone app reduced depression symptoms in participants on antidepressant medication with no treatment-related adverse events

    Read More

    Jan 08, 2024

    NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

    Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023, beginning 2024 with cash balance of $66.5 million.

    Announced completion of patient implant milestone in the NAUTILUS trial.

    Completed initial milestones in first strategic data collaboration, using proprietary biomarker monitoring and data analysis capabilities to support a clinical-stage biotechnology company’s clinical trial.

    Pilot Launch of Project CARE program to advance RNS System access to community setting expected in 1H 2024.

    Dec 21, 2023

    NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

    NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy. Neuromodulation therapy is not currently indicated for patients with drug refractory generalized epilepsy. If successful, NeuroPace’s RNS System would represent the first neuromodulation indication in idiopathic generalized epilepsy

    Dec 05, 2023

    NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration

    First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial. In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients

    Contact Us

    Partner with Us

    Get in touch